On November 15, 2018 Fusion Pharmaceuticals, a biopharmaceutical company focused on radiotherapeutics (specifically, targeted alpha therapeutics), reported that it will present at two separate conferences this week (Press release, Fusion Pharmaceuticals, OCT 15, 2018, View Source [SID1234531595]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On Tuesday, October 16, 2018, Fusion will present scientific data on its lead program FPI-1434 at the European Association of Nuclear Medicine (EANM) 2018 Congress. The meeting is behind held in the CCD, Congress Center Dusseldorf, in Dusseldorf, Germany.

On Thursday, October 18, 2018, at 10:00am PT, Fusion will present at the BIO Investor Forum 2018. The event is being held at the Westin St. Francis Hotel in San Francisco, California.